Curaleaf Laboratories, part of Curaleaf International, today announced the UK launch of the Curaleaf Que Medical Inhalation Device (QMID), the first CE-certified liquid inhaler for cannabis-based medicines. Available on prescription, the device offers patients a precise, discreet, and clinically approved way to inhale cannabis-based treatments.
Since the law changed in the UK in 2018, allowing specialist doctors to prescribe cannabis-based products for medicinal use (CBPMs), more than 60,000 patients have gained access. Among this growing population, one of the biggest unmet needs has been a discreet and reliable inhalation option — now addressed with the launch of the Curaleaf Que Medical Inhalation Device.
Patients are also seeking greater choice in how they take their medicines, and Curaleaf Laboratories has responded with an expanded range that now includes oils, dried flower, pastilles, capsules, topicals, and vaporisation options. In parallel, Curaleaf is working closely with regulatory bodies in markets including Germany, Poland, Australia, and others to secure registration of the device and expand patient access wherever permitted.
The EU Class IIa device, according to the EU Medical Device Regulation (EU 2017/745), enables consistent, controlled delivery of liquid cannabis extracts, offering a new and approved option for eligible patients who are appropriate for inhaled cannabis medicines. The new device has been tested and certified for safety, reliability, and repeatability across multiple use cases required for medical certification.
Jonathan Hodgson, UK Managing Director at Curaleaf International, commented: “For the first time, inhaled liquid cannabis can be administered with controlled precision through a registered handheld device — giving prescribers and patients new confidence in treatment delivery. Unlike unregulated or consumer-grade vaporisers, this device is purpose-built for clinical use, with standardised delivery, medical-grade components, and compatibility with formulations that meet European Pharmacopoeia standards.”
The Curaleaf Que Medical Inhalation Device, designed in partnership with Jupiter Research LLC, a subsidiary of TILT Holdings, developed and based on Jupiter’s intellectual property, is a purpose-built medical device. Key features include:
The device is only compatible with Curaleaf’s EU-GMP liquid extract cartridges, available to all medical cannabis clinics.
Juan Martinez, International CEO at Curaleaf, said: “The launch of this certified Curaleaf device reflects the next phase of innovation and positions Curaleaf at the forefront of a differentiated, pharma-grade delivery platform that addresses growing global demand for precision cannabis therapies. It’s part of our wider mission to make medical cannabis more accessible, more consistent, and integrated into mainstream healthcare systems.”
Curaleaf International continues to collaborate with regulators, healthcare providers, and pharmacists across the globe to expand safe access to cannabinoid-based medicines in line with evolving clinical guidelines.
The post Curaleaf Laboratories launches first certified liquid medical cannabis inhaler for UK patients appeared first on Cannabis Health News.
Continue reading...
Since the law changed in the UK in 2018, allowing specialist doctors to prescribe cannabis-based products for medicinal use (CBPMs), more than 60,000 patients have gained access. Among this growing population, one of the biggest unmet needs has been a discreet and reliable inhalation option — now addressed with the launch of the Curaleaf Que Medical Inhalation Device.
Patients are also seeking greater choice in how they take their medicines, and Curaleaf Laboratories has responded with an expanded range that now includes oils, dried flower, pastilles, capsules, topicals, and vaporisation options. In parallel, Curaleaf is working closely with regulatory bodies in markets including Germany, Poland, Australia, and others to secure registration of the device and expand patient access wherever permitted.
The EU Class IIa device, according to the EU Medical Device Regulation (EU 2017/745), enables consistent, controlled delivery of liquid cannabis extracts, offering a new and approved option for eligible patients who are appropriate for inhaled cannabis medicines. The new device has been tested and certified for safety, reliability, and repeatability across multiple use cases required for medical certification.
Jonathan Hodgson, UK Managing Director at Curaleaf International, commented: “For the first time, inhaled liquid cannabis can be administered with controlled precision through a registered handheld device — giving prescribers and patients new confidence in treatment delivery. Unlike unregulated or consumer-grade vaporisers, this device is purpose-built for clinical use, with standardised delivery, medical-grade components, and compatibility with formulations that meet European Pharmacopoeia standards.”
The Curaleaf Que Medical Inhalation Device, designed in partnership with Jupiter Research LLC, a subsidiary of TILT Holdings, developed and based on Jupiter’s intellectual property, is a purpose-built medical device. Key features include:
- CE-certified and Class IIa approved
The Curaleaf Inhalation device meets European safety and quality standards. Its medical device certification gives prescribers and patients confidence in its therapeutic suitability and regulatory compliance. - Precise, standardised timed dosing
The quantity of medication delivered by the device and cartridge has been measured using internationally recognised criteria. This ensures reliable delivery across all administrations and devices — critical for consistent patient administration. - Designed for real patients
The device activates on inhalation, with no buttons or menus. It’s simple to use, discreet, and well-suited for both clinical supervision and home use. - Reusable, long-lasting hardware
Rechargeable, with a minimum lifespan of 6 months from first use, the replaceable 0.5 mL and 1.0 mL cartridges deliver up to 240 inhalations with the 1.0mL cartridge.
The device is only compatible with Curaleaf’s EU-GMP liquid extract cartridges, available to all medical cannabis clinics.
Juan Martinez, International CEO at Curaleaf, said: “The launch of this certified Curaleaf device reflects the next phase of innovation and positions Curaleaf at the forefront of a differentiated, pharma-grade delivery platform that addresses growing global demand for precision cannabis therapies. It’s part of our wider mission to make medical cannabis more accessible, more consistent, and integrated into mainstream healthcare systems.”
Curaleaf International continues to collaborate with regulators, healthcare providers, and pharmacists across the globe to expand safe access to cannabinoid-based medicines in line with evolving clinical guidelines.
The post Curaleaf Laboratories launches first certified liquid medical cannabis inhaler for UK patients appeared first on Cannabis Health News.
Continue reading...
